Chugai Pharmaceutical Co., Ltd. (CHGCY) Stock Price & Analysis
Chugai Pharmaceutical Co., Ltd. (CHGCY) — price $22.46 (+0.58%), as of the Nov 19, 2026 trading session; market cap $73.9B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Chugai Pharmaceutical Co., Ltd. · CHGCY · Healthcare · Drug Manufacturers - General
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $22.46 | |
| Change on the day | +0.58% | |
| 52-week range | $18.33–$34.84 | |
| Market capitalisation | $73.9B | — |
| Price / earnings (trailing) | 23.54 | |
| Shares traded on the day | 99.0K | |
| Beta (volatility vs the S&P 500) | 0.56 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
- · Earnings results
- · Earnings results
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Chugai Pharmaceutical Co. (CHGCY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Chugai Pharmaceutical Co. (CHGCY), and what does it report?
Short answer
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. Healthcare / Drug Manufacturers General SEC filing business address: 120 Broadway, 32ND Floor, NEW York, NY, 10271. It employs 7,872 people and is led by Osamu Okuda. In Q3 FY2026 it reported revenue of ¥404.74B and net income of ¥143.55B. The market values it at $73.9B.
What do the latest results show for Chugai Pharmaceutical Co. (CHGCY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of ¥404.74B.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $2.56B Oct 27, 2026
- Latest report · revenue estimate
- $2.17B Oct 27, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 27, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 27, 2026 | $2.56B | $2.17B | $0.2700 | Not available |
| Jul 24, 2026 | $2.14B | $2.16B | $0.2200 | Not available |
| Apr 24, 2026 | $2.05B | $1.95B | $0.2200 | Not available |
| Jan 29, 2026 | $2.56B | $1.84B | $0.2500 | Not available |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | ¥404.74B | ¥143.55B | ¥42.97 (diluted) |
| Q2 FY2026 | ¥346.08B | ¥117.86B | ¥35.52 (diluted) |
| Q1 FY2026 | ¥327.66B | ¥117.54B | ¥35.15 (diluted) |
| Q4 FY2025 | ¥401.48B | ¥147.51B | ¥44.82 (diluted) |
What are the financial strengths and risks for Chugai Pharmaceutical Co. (CHGCY)?
Short answer · as of
The distress and quality screens read Altman Z 28.67 · Piotroski F 7. Trailing ratios: ROE 25.0% · ROA 21.2% · current ratio 6.39 · earnings yield 4.1% · free-cash-flow yield 3.0%.
What should you watch next at Chugai Pharmaceutical Co. (CHGCY)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No forward revenue or earnings estimate is on file.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CHGCY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CHGCY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Chugai Pharmaceutical Co. (CHGCY)?
- Chugai Pharmaceutical Co., Ltd. (CHGCY) Q3 2026 Earnings Call Transcript
- Financial Analysis: Chugai Pharmaceutical (OTCMKTS:CHGCY) & Theravance Biopharma (NASDAQ:TBPH)
- Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 52-Week Low – Should You Sell?
- Analyzing Chugai Pharmaceutical (OTCMKTS:CHGCY) & Ascend Wellness (OTCMKTS:AAWH)
CHGCY Healthcare Stock FAQ
These answers are editorial: 1 of these 8 answers is drawn from the CHGCY research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CHGCY a good stock to buy?
Stock Expert AI does not rate CHGCY buy, sell or hold. Chugai Pharmaceutical Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CHGCY stock price today?
The last price recorded for Chugai Pharmaceutical Co., Ltd. (CHGCY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is Chugai Pharmaceutical Co., Ltd.'s approach to research and development for new pharmaceutical candidates?
Chugai Pharmaceutical Co., Ltd. employs a robust and innovation-driven approach to research and development, central to its long-term growth strategy.
What are the key factors to evaluate for CHGCY?
Evaluate CHGCY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. The market for these chronic conditions is substantial and offers long-term growth potential as new therapies emerge from its pipeline. Not financial advice.
How frequently does CHGCY data refresh on this page?
CHGCY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CHGCY's recent stock price performance?
Chugai Pharmaceutical Co., Ltd. (CHGCY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong strategic alliance with Roche Group, enhancing R&D and global market access. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHGCY overvalued or undervalued right now?
The trailing P/E of Chugai Pharmaceutical Co., Ltd. (CHGCY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CHGCY before investing?
Before investing in Chugai Pharmaceutical Co., Ltd. (CHGCY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 33 figures on this page — 1 from SEC filings and earnings calls, 27 from Financial Modeling Prep (FMP), 3 with no recorded source, 1 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com